Contact
searchSearch
HMP Global
Login

Psych Congress Network

Latest News, Insights, and Quizzes

Conference attendees look at a poster
Conference Coverage
Digital Therapeutic Rejoyn May Aid Anxiety in MDD Patients
09/25/2025
Brionna Mendoza
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
The digital therapeutic Rejoyn...
09/25/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Managing Common Medical Comorbidities in Schizophrenia
09/23/2025
Amber Hoberg, MSN, APRN, PMHNP-BC
In this video taken on-site at the 2025 Psych Congress, Steering Committee Member Amber Hoberg, PMHNP-BC, walks clinicians through her approach to managing some common comorbid conditions that may impact schizophrenia patients.
In this video taken on-site at the 2025 Psych Congress, Steering Committee Member Amber Hoberg, PMHNP-BC, walks clinicians through her approach to managing some common comorbid conditions that may impact schizophrenia patients.
In this video taken on-site at...
09/23/2025
Psych Congress Network
Kristin Lasseter, MD
Q&A
Improving PMDD Care Through Accurate Diagnosis and Emerging Treatments
09/21/2025
In this insightful Q&A, Kristin Lasseter, MD, shares insights from her 2025 Psych Congress session, “PMDD Uncovered: Neurobiological Insights and Treatment Innovations.”
In this insightful Q&A, Kristin Lasseter, MD, shares insights from her 2025 Psych Congress session, “PMDD Uncovered: Neurobiological Insights and Treatment Innovations.”
In this insightful Q&A, Kristin...
09/21/2025
Psych Congress Network
Mark Zimmerman, MD
Conference Coverage
Are We Overlooking Anger in Psychiatric Practice?
09/20/2025
Mark Zimmerman, MD
Mark Zimmerman, MD, shares some of the takeaways from his session presented at the 2025 Psych Congress titled "'I’m So Angry There Are No Talks About Anger': Recognizing and Managing Anger (the Overlooked Affect) in Clinical Practice."
Mark Zimmerman, MD, shares some of the takeaways from his session presented at the 2025 Psych Congress titled "'I’m So Angry There Are No Talks About Anger': Recognizing and Managing Anger (the Overlooked Affect) in Clinical Practice."
Mark Zimmerman, MD, shares some...
09/20/2025
Psych Congress Network
Katherine Warburton, Stephen Stahl, and Roberto Carrara
News
Breaking the Cycle of Criminalization: Keynote Address Tackles Neuroethics, Justice Reform, and Patient Autonomy at Psych Congress 2025
09/19/2025
Maria Mantas
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical...
09/19/2025
Psych Congress Network
A poster hall at a conference
Conference Coverage
Added Seltorexant Shows Robust Response With Fewer Adverse Events in MDD With Insomnia
09/19/2025
Jolynn Tumolo
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
In patients with major...
09/19/2025
Psych Congress Network
Charles Raison, MD
Conference Coverage
How the Depression-Inflammation Connection is Reshaping Treatment Paradigms
09/18/2025
Charles L. Raison, MD
In this interview, Charles Raison, MD, Psych Congress Steering Committee Member, shares some of the key insights from his session presented at the 2025 Psych Congress: “The Role of Inflammation in Depression: Bridging Science and Clinical...
In this interview, Charles Raison, MD, Psych Congress Steering Committee Member, shares some of the key insights from his session presented at the 2025 Psych Congress: “The Role of Inflammation in Depression: Bridging Science and Clinical...
In this interview, Charles...
09/18/2025
Psych Congress Network
Speakers on stage at the Vladimir Maletic memorial session
Conference Coverage
Dr Vladimir Maletic’s Life and Legacy Honored at 38th Annual Psych Congress
09/17/2025
Brionna Mendoza
The first day of the 38th annual Psych Congress featured a moving tribute session given in memory of Vladimir Maletic, MD, MS, a clinical professor of psychiatry and behavioral science at the University of South Carolina School of Medicine in...
The first day of the 38th annual Psych Congress featured a moving tribute session given in memory of Vladimir Maletic, MD, MS, a clinical professor of psychiatry and behavioral science at the University of South Carolina School of Medicine in...
The first day of the 38th annual...
09/17/2025
Psych Congress Network
DNA strand
News
Pharmacogenomic Test Improves MDD Response and Remission Outcomes
09/15/2025
Jolynn Tumolo
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific...
09/15/2025
Psych Congress Network
Michael Asbach
Conference Preview
Psych Congress: The Big Tent of Psychiatry
09/12/2025
Michael Asbach, DMSc, PA-C
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C,...
09/12/2025
Psych Congress Network

Latest Expert Insights

Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Managing Common Medical Comorbidities in Schizophrenia
09/23/2025
Amber Hoberg, MSN, APRN, PMHNP-BC
In this video taken on-site at the 2025 Psych Congress, Steering Committee Member Amber Hoberg, PMHNP-BC, walks clinicians through her approach to managing some common comorbid conditions that may impact schizophrenia patients.
In this video taken on-site at the 2025 Psych Congress, Steering Committee Member Amber Hoberg, PMHNP-BC, walks clinicians through her approach to managing some common comorbid conditions that may impact schizophrenia patients.
In this video taken on-site at...
09/23/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 7: Sleep is the Foundation of Mental Health
09/12/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common,...
09/12/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Billing, Reimbursement, and Maximizing Revenue for Telehealth Services
09/09/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress...
09/09/2025
Psych Congress Network
Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 6: Psychiatry Is the Specialty That Speaks for Those Without a Voice
09/08/2025
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than...
09/08/2025
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Shaping the Future of Schizophrenia Care With Muscarinic-Targeting Treatments
09/05/2025
Brooke Kempf, MSN, PMHNP-BC
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress...
09/05/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Hypersomnolence in Individuals With Mental Illness
09/05/2025
Craig Chepke, MD, DFAPA
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA,...
09/05/2025
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Navigating Regulations Regarding the Prescription of Controlled Substances via Telehealth
09/03/2025
Edward Kaftarian, MD
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych...
09/03/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 5: We’re Too Addicted to Our Own Good Ideas
08/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain...
08/25/2025
Psych Congress Network

From the Newsrooms

Conference attendees look at a poster
Conference Coverage
Digital Therapeutic Rejoyn May Aid Anxiety in MDD Patients
09/25/2025
Brionna Mendoza
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
The digital therapeutic Rejoyn...
09/25/2025
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Managing Common Medical Comorbidities in Schizophrenia
09/23/2025
Amber Hoberg, MSN, APRN, PMHNP-BC
In this video taken on-site at the 2025 Psych Congress, Steering Committee Member Amber Hoberg, PMHNP-BC, walks clinicians through her approach to managing some common comorbid conditions that may impact schizophrenia patients.
In this video taken on-site at the 2025 Psych Congress, Steering Committee Member Amber Hoberg, PMHNP-BC, walks clinicians through her approach to managing some common comorbid conditions that may impact schizophrenia patients.
In this video taken on-site at...
09/23/2025
Psych Congress Network
Kristin Lasseter, MD
Q&A
Improving PMDD Care Through Accurate Diagnosis and Emerging Treatments
09/21/2025
In this insightful Q&A, Kristin Lasseter, MD, shares insights from her 2025 Psych Congress session, “PMDD Uncovered: Neurobiological Insights and Treatment Innovations.”
In this insightful Q&A, Kristin Lasseter, MD, shares insights from her 2025 Psych Congress session, “PMDD Uncovered: Neurobiological Insights and Treatment Innovations.”
In this insightful Q&A, Kristin...
09/21/2025
Psych Congress Network
Mark Zimmerman, MD
Conference Coverage
Are We Overlooking Anger in Psychiatric Practice?
09/20/2025
Mark Zimmerman, MD
Mark Zimmerman, MD, shares some of the takeaways from his session presented at the 2025 Psych Congress titled "'I’m So Angry There Are No Talks About Anger': Recognizing and Managing Anger (the Overlooked Affect) in Clinical Practice."
Mark Zimmerman, MD, shares some of the takeaways from his session presented at the 2025 Psych Congress titled "'I’m So Angry There Are No Talks About Anger': Recognizing and Managing Anger (the Overlooked Affect) in Clinical Practice."
Mark Zimmerman, MD, shares some...
09/20/2025
Psych Congress Network
Katherine Warburton, Stephen Stahl, and Roberto Carrara
News
Breaking the Cycle of Criminalization: Keynote Address Tackles Neuroethics, Justice Reform, and Patient Autonomy at Psych Congress 2025
09/19/2025
Maria Mantas
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical...
09/19/2025
Psych Congress Network
A poster hall at a conference
Conference Coverage
Added Seltorexant Shows Robust Response With Fewer Adverse Events in MDD With Insomnia
09/19/2025
Jolynn Tumolo
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
In patients with major...
09/19/2025
Psych Congress Network
Charles Raison, MD
Conference Coverage
How the Depression-Inflammation Connection is Reshaping Treatment Paradigms
09/18/2025
Charles L. Raison, MD
In this interview, Charles Raison, MD, Psych Congress Steering Committee Member, shares some of the key insights from his session presented at the 2025 Psych Congress: “The Role of Inflammation in Depression: Bridging Science and Clinical...
In this interview, Charles Raison, MD, Psych Congress Steering Committee Member, shares some of the key insights from his session presented at the 2025 Psych Congress: “The Role of Inflammation in Depression: Bridging Science and Clinical...
In this interview, Charles...
09/18/2025
Psych Congress Network
Speakers on stage at the Vladimir Maletic memorial session
Conference Coverage
Dr Vladimir Maletic’s Life and Legacy Honored at 38th Annual Psych Congress
09/17/2025
Brionna Mendoza
The first day of the 38th annual Psych Congress featured a moving tribute session given in memory of Vladimir Maletic, MD, MS, a clinical professor of psychiatry and behavioral science at the University of South Carolina School of Medicine in...
The first day of the 38th annual Psych Congress featured a moving tribute session given in memory of Vladimir Maletic, MD, MS, a clinical professor of psychiatry and behavioral science at the University of South Carolina School of Medicine in...
The first day of the 38th annual...
09/17/2025
Psych Congress Network
Brittany Albright and Kristian Dambrino
Clinical Pearls
Knowing When to Refer a Patient for Esketamine
09/16/2025
Brittany B. Albright, MD, MPH; Kristian Dambrino, MSN, APRN, PMHNP
Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC,, discuss referral practices for esketamine and transcranial magnetic stimulation for patients with depression.
Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC,, discuss referral practices for esketamine and transcranial magnetic stimulation for patients with depression.
Brittany Albright, MD, MPH, and...
09/16/2025
Psych Congress NP Institute
Michael Asbach
Conference Preview
Psych Congress: The Big Tent of Psychiatry
09/12/2025
Michael Asbach, DMSc, PA-C
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C,...
09/12/2025
Psych Congress Network

Quizzes

a cloud with three z's
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 1)
09/19/2025
Can you optimize ADHD control and protect sleep? Take this quick quiz on viloxazine ER’s role in patients with nighttime challenges.
Can you optimize ADHD control and protect sleep? Take this quick quiz on viloxazine ER’s role in patients with nighttime challenges.
Can you optimize ADHD control...
09/19/2025
Psych Congress Network
Dr Greg Mattingly
Quiz
Test Your Knowledge – Viloxazine ER: A New Era in ADHD Treatment?
09/17/2025
How well do you know the clinical impact and unique mechanism of viloxazine ER? Take this short quiz to find out.
How well do you know the clinical impact and unique mechanism of viloxazine ER? Take this short quiz to find out.
How well do you know the...
09/17/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia
09/12/2025
Craig Chepke, MD, DFAPA
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of...
09/12/2025
Psych Congress Network
medication
Quiz
Test Your Knowledge: Study Results Link Non-Stimulant ADHD Therapy and Prescription Stimulant Misuse in Adolescents
09/09/2025
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about...
09/09/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge – Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
09/04/2025
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of...
09/04/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge: Dr Rakesh Jain on Nonstimulant Treatment Options for Pediatric ADHD
09/03/2025
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the...
09/03/2025
Psych Congress Network
Wooden blocks spelling QUIZ
Quiz
Test Your Knowledge: Viloxazine ER Added to Stimulant Treatment for Pediatric ADHD Appears Safe, Effective
09/02/2025
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance...
09/02/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 3
Quiz
Test Your Knowledge – Navigating ADHD Care Forward: The Future of ADHD
08/27/2025
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test...
08/27/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 2
Quiz
Test Your Knowledge – Real-World Data Deep Dive: Viloxazine ER Compared With Atomoxetine for ADHD Study
08/25/2025
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER...
08/25/2025
Psych Congress Network
blocks spelling out the word "quiz"
Quiz
Initiating Clozapine in Patients With Schizophrenia
08/15/2025
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following...
08/15/2025
Psych Congress Network

Recent FDA Updates

fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
FDA building
News
FDA Advisory Committee Votes Against Brexpiprazole Indication for Treatment of PTSD Following Efficacy Concerns
07/21/2025
Maria Mantas
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD).  
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD).  
The US Food and Drug...
07/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network

Live Meetings

Psych Congress Family & Friends Podcast

Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 7: Sleep is the Foundation of Mental Health
09/12/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common,...
09/12/2025
Psych Congress Network
Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 6: Psychiatry Is the Specialty That Speaks for Those Without a Voice
09/08/2025
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than...
09/08/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 5: We’re Too Addicted to Our Own Good Ideas
08/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain...
08/25/2025
Psych Congress Network
craig chepke and rakesh jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 4: Every Pill is a Choice
07/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
They are back! Through a...
07/25/2025
Psych Congress Network
Rakesh and Craig
Podcasts
Weighing the Options: Medication, Lifestyle, and the Path to Wellness
03/26/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain...
03/26/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use